Tech
Click Therapeutics leader talks digital treatments, dangers of unlimited AI
A convo with Viveca Livezey, Click’s SVP of clinical development and evidence generation.
Caroline joined Healthcare Brew in July 2024 after three years as a health reporter for the Orlando Sentinel. Her work has appeared in outlets including CNN, Science Magazine, and The Chicago Tribune. She holds a master’s in health, environment, and science journalism from Northwestern University and degrees in psychology and English from Emory University, where she was first author on a public health study. Get in touch: [email protected]
Pharma
Despite FDA crackdown, unapproved GLP-1s still threaten the industry
Legitimate compounders are threatened by false advertising of counterfeit GLP-1s, legal experts warn.
Payers
Curative CEO Fred Turner explains why his alternative health plan is valued at $1.3b
The Covid test-provider-turned-insurer touts $0 copays, deductibles, and coinsurance for members who get preventative care.
Pharma
Could relaxed regulations boost gene therapy for ultra-rare diseases?
Companies like Prime Medicine and Aurora Therapeutics are shooting their shot.
Tech
ChatGPT Health fails to send patients to the emergency room over half the time: study
We hope the bot knows a good eye doctor because it has some blind spots.
Hospitals & Facilities
Physicians still waiting for CMS clarity on anti-workplace violence signs
A sign is one small part of preventing workplace violence. But it’s still important, doctors say.
Payers
Silna Health CEO on balancing urgency with accuracy within prior authorization
Morelli talked to us about the danger of fragmented health tech and the push for end-to-end automation.
Payers
What happens when nearly an entire state is kicked off Medicare Advantage?
Forced disenrollments are spiking for MA beneficiaries as payers reduce options, a new study finds.
Pharma
GoodRx, Eli Lilly launch direct-to-employer models that reduce reliance on PBMs
Is direct to employer the new direct to consumer?
Payers
CMS threat to Elevance could bring financial consequences
A long-running dispute over risk scores is coming to a head.